# Taiyu Investment

> Taiyu Investment is a VC fund in Beijing backing Medical, Health Care and Biotechnology. See 17 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Beijing, China
- Total investments: 17
- Last investment: Jul 2023
- Lead investor: 6%
- Last updated: Aug 2026
- Website: http://www.tigeryeah.com/

Taiyu Investment is an investment firm.

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $16M–$20M |
| Angel | $425k–$425k |
| Series A | $13M–$16M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 10 | 59% |
| Health Care | 8 | 47% |
| Biotechnology | 5 | 29% |
| Medical Device | 4 | 24% |
| Biopharma | 2 | 12% |

17 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 6 | 35% |
| Seed | 4 | 24% |
| Angel | 3 | 18% |
| Series C | 2 | 12% |
| Series B | 1 | 6% |

6 stages tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Weixin Medical | Weixin Medical is an innovative medical device platform for women's health. |  | Series A | Jul 10, 2023 |  |
| ChomiX Biotech | ChomiX Biotech will always manage the company's development with a realistic, disciplined, and excellence-driven scientific research mindset. In addition, the company will use cutting-edge technology to solve problems for clients and generate revenue. We can only see the stars if we stay grounded. ChomiX will continue to research and developits own core technology in order to continually maintain its top rank on the track and steer the development of the industry. |  | Seed | May 15, 2023 |  |
| Immorna | Immorna specializes in the production of RNA-based therapeutics. | $13M | Series A | Feb 27, 2023 |  |
| Leadinno Medical Valley | Leadino Medical Valley is a producer of medical devices for neuroregulatory functions. | $14.4M | Series A | Sep 09, 2022 |  |
| Epigenic Therapeutics | Epigenic Therapeutics is a biotech firm that offers gene editing therapy. | $20M | Seed | Aug 06, 2022 |  |
| Tingsheng Technology | TINGSN develops Intracardiac echocardiography (ICE) catheter imaging technology designed to treat cardiac arrhythmia. In addition to ICE products, the company has developed its own heart internal catheter positioning and software algorithms and is developing China first computer surgical simulator for cardiac electrophysiology based on digitalheart model. | $15.8M | Series A | Mar 03, 2022 |  |
| Enze Kangtai | Echo Biotech is a biotech firm mainly engaged in the R&D and production of exosome molecular diagnostic products and exosome research. |  | Series A | Jan 11, 2022 |  |
| Hesguard | Hesguard is a medical device developer and producer of high-end implantable medical devices related to ophthalmic diseases. | $15.7M | Seed | Dec 26, 2021 |  |
| Hangzhou DAC Biotech Co., Ltd | Hangzhou DAC Biotech Co., Ltd focuses on developing conjugate of monoclonal antibody and small molecular cytotoxic drugs. | $154.9M | Series C | May 12, 2021 |  |
| Novamab | Novamab focuses on the research and development of new nanobodies. The core members of the team have 15 years of experience in nanobody research and development, and are domestic nanobody "pioneers". At present, they have established an inhaled macromolecular drug research and development platform, an albumin nanobody long-acting platformand a nanobody double-antibody platform, etc., to give full play to nanobody The advantages of antibodies, the development of innovative nanobody drugs such as sprays and eye drops, to solve the pain points of clinical major chronic diseases in terms of administration methods, administration cycles, etc. | $15.4M | Series A | Mar 12, 2021 |  |

10 of 17 investments shown.

## Co-investors
- [Taiyu Investment](https://shizune.co/investors/profile/taiyu-investment) — VC Fund, 12 deals together
- [Tigermed](https://shizune.co/investors/profile/hangzhou-tigermed-technology-co-ltd) — VC Fund, 2 deals together
- [Med-Fine Capital](https://shizune.co/investors/profile/med-fine-capital) — VC Fund, 2 deals together
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund, 2 deals together
- [Anji Yunshuo](https://shizune.co/investors/profile/anji-yunshuo) — VC Fund, 1 deal together
- [Baidu Ventures](https://shizune.co/investors/profile/baidu-ventures) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [IDG Capital](https://shizune.co/investors/profile/idg-capital-partners) — VC Fund
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund
- [HSG](https://shizune.co/investors/profile/sequoia-capital-china) — VC Fund

## Featured in investor lists
- [Health Care Investors in China](https://shizune.co/investors/health-care-investors-china)
- [Health Care VC Funds in China](https://shizune.co/investors/health-care-vc-funds-china)
- [Medical Investors in Asia](https://shizune.co/investors/medical-investors-asia)
- [Medical VC Funds in Asia](https://shizune.co/investors/medical-vc-funds-asia)
- [Medical Investors in China](https://shizune.co/investors/medical-investors-china)
- [Medical VC Funds in China](https://shizune.co/investors/medical-vc-funds-china)

## FAQ

### What does Taiyu Investment invest in?

Taiyu Investment invests primarily in Medical, Health Care and Biotechnology startups, most often at Series A and Seed stage. Most of the 17 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Taiyu Investment's check size?

Taiyu Investment typically joins rounds of $16M–$20M at Seed, $425k–$425k at Angel and $13M–$16M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Taiyu Investment participates in.

### When did Taiyu Investment last invest?

The most recent investment recorded for Taiyu Investment closed in Jul 2023. Shizune tracks 17 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co